Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 May;71(5):914–924. doi: 10.1038/bjc.1995.178

Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.

A L Jackman 1, L R Kelland 1, R Kimbell 1, M Brown 1, W Gibson 1, G W Aherne 1, A Hardcastle 1, F T Boyle 1
PMCID: PMC2033796  PMID: 7537518

Abstract

Four cell lines, the mouse L1210 leukaemia, the human W1L2 lymphoblastoid and two human ovarian (CH1 and 41M) cell lines, were made resistant to ZD1694 (Tomudex) by continual exposure to incremental doses of the drug. A 500-fold increase in thymidylate synthase (TS) activity is the primary mechanism of resistance to ZD1694 in the W1L2:RD1694 cell line, which is consequently highly cross-resistant to other folate-based TS inhibitors, including BW1843U89, LY231514 and AG337, but sensitive to antifolates with other enzyme targets. The CH1:RD1694 cell line is 14-fold resistant to ZD1694, largely accounted for by the 4.2-fold increase in TS activity. Cross-resistance was observed to other TS inhibitors, including 5-fluorodeoxyuridine (FdUrd). 41M:RD1694 cells, when exposed to 0.1 microM [3H]ZD1694, accumulated approximately 20-fold less 3H-labelled material over 24 h than the parental line. Data are consistent with this being the result of impaired transport of the drug via the reduced folate/methotrexate carrier. Resistance was therefore observed to methotrexate but not to CB3717, a compound known to use this transport mechanism poorly. The mouse L1210:RD1694 cell line does not accumulate ZD1694 or Methotrexate (MTX) polyglutamates. Folylpolyglutamate synthetase substrate activity (using ZD1694 as the substrate) was decreased to approximately 13% of that observed in the parental line. Cross-resistance was found to those compounds known to be active through polyglutamation.

Full text

PDF
914

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Assaraf Y. G., Feder J. N., Sharma R. C., Wright J. E., Rosowsky A., Shane B., Schimke R. T. Characterization of the coexisting multiple mechanisms of methotrexate resistance in mouse 3T6 R50 fibroblasts. J Biol Chem. 1992 Mar 25;267(9):5776–5784. [PubMed] [Google Scholar]
  2. Baskin F., Carlin S. C., Kraus P., Friedkin M., Rosenberg R. N. Experimental chemotherapy of neuroblastoma. II. Increased thymidylate synthetase activity in a 5-fluorodeoxyuridine-resistant variant of mouse neuroblastoma. Mol Pharmacol. 1975 Jan;11(1):105–117. [PubMed] [Google Scholar]
  3. Bavetsias V., Jackman A. L., Thornton T. J., Pawelczak K., Boyle F. T., Bisset G. M. Quinazoline antifolates inhibiting thymidylate synthase: synthesis of gamma-linked peptide and amide analogues of 2-desamino-2-methyl-N10-propargyl- 5,8-dideazafolic acid (ICI 198583). Adv Exp Med Biol. 1993;338:593–596. doi: 10.1007/978-1-4615-2960-6_121. [DOI] [PubMed] [Google Scholar]
  4. Berger S. H., Jenh C. H., Johnson L. F., Berger F. G. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol. 1985 Nov;28(5):461–467. [PubMed] [Google Scholar]
  5. Boyle F. T., Matusiak Z. S., Hughes L. R., Slater A. M., Stephens T. C., Smith M. N., Brown M., Kimbell R., Jackman A. L. Substituted-2-desamino-2-methyl-quinazolinones. A series of novel antitumour agents. Adv Exp Med Biol. 1993;338:585–588. doi: 10.1007/978-1-4615-2960-6_119. [DOI] [PubMed] [Google Scholar]
  6. Calvert A. H., Alison D. L., Harland S. J., Robinson B. A., Jackman A. L., Jones T. R., Newell D. R., Siddik Z. H., Wiltshaw E., McElwain T. J. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol. 1986 Aug;4(8):1245–1252. doi: 10.1200/JCO.1986.4.8.1245. [DOI] [PubMed] [Google Scholar]
  7. Chabner B. A., Allegra C. J., Curt G. A., Clendeninn N. J., Baram J., Koizumi S., Drake J. C., Jolivet J. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985 Sep;76(3):907–912. doi: 10.1172/JCI112088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Clark J. L., Berger S. H., Mittelman A., Berger F. G. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep. 1987 Mar;71(3):261–265. [PubMed] [Google Scholar]
  9. Cowan K. H., Jolivet J. A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J Biol Chem. 1984 Sep 10;259(17):10793–10800. [PubMed] [Google Scholar]
  10. Curtin N. J., Harris A. L., Aherne G. W. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 1991 May 1;51(9):2346–2352. [PubMed] [Google Scholar]
  11. Danenberg K. D., Danenberg P. V. Activity of thymidylate synthetase and its inhibition by 5-fluorouracil in highly enzyme-overproducing cells resistant to 10-propargyl-5,8-dideazafolate. Mol Pharmacol. 1989 Aug;36(2):219–223. [PubMed] [Google Scholar]
  12. Duch D. S., Banks S., Dev I. K., Dickerson S. H., Ferone R., Heath L. S., Humphreys J., Knick V., Pendergast W., Singer S. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res. 1993 Feb 15;53(4):810–818. [PubMed] [Google Scholar]
  13. Fry D. W., Besserer J. A., Boritzki T. J. Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res. 1984 Aug;44(8):3366–3370. [PubMed] [Google Scholar]
  14. Galivan J. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol. 1980 Jan;17(1):105–110. [PubMed] [Google Scholar]
  15. Gibson W., Bisset G. M., Marsham P. R., Kelland L. R., Judson I. R., Jackman A. L. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells. Biochem Pharmacol. 1993 Feb 24;45(4):863–869. doi: 10.1016/0006-2952(93)90170-2. [DOI] [PubMed] [Google Scholar]
  16. Hills C. A., Kelland L. R., Abel G., Siracky J., Wilson A. P., Harrap K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989 Apr;59(4):527–534. doi: 10.1038/bjc.1989.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hughes L. R., Jackman A. L., Oldfield J., Smith R. C., Burrows K. D., Marsham P. R., Bishop J. A., Jones T. R., O'Connor B. M., Calvert A. H. Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 position. J Med Chem. 1990 Nov;33(11):3060–3067. doi: 10.1021/jm00173a024. [DOI] [PubMed] [Google Scholar]
  18. Imam A. M., Crossley P. H., Jackman A. L., Little P. F. Analysis of thymidylate synthase gene amplification and of mRNA levels in the cell cycle. J Biol Chem. 1987 May 25;262(15):7368–7373. [PubMed] [Google Scholar]
  19. Jackman A. L., Alison D. L., Calvert A. H., Harrap K. R. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies. Cancer Res. 1986 Jun;46(6):2810–2815. [PubMed] [Google Scholar]
  20. Jackman A. L., Bisset G. M., Jodrell D. I., Gibson W., Kimbell R., Bavetsias V., Calvert A. H., Harrap K. R., Stephens T. C., Smith M. N. Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8- dideazafolate as antitumour agents. Adv Exp Med Biol. 1993;338:579–584. doi: 10.1007/978-1-4615-2960-6_118. [DOI] [PubMed] [Google Scholar]
  21. Jackman A. L., Marsham P. R., Moran R. G., Kimbell R., O'Connor B. M., Hughes L. R., Calvert A. H. Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolates. Adv Enzyme Regul. 1991;31:13–27. doi: 10.1016/0065-2571(91)90006-8. [DOI] [PubMed] [Google Scholar]
  22. Jackman A. L., Newell D. R., Gibson W., Jodrell D. I., Taylor G. A., Bishop J. A., Hughes L. R., Calvert A. H. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem Pharmacol. 1991 Oct 24;42(10):1885–1895. doi: 10.1016/0006-2952(91)90586-t. [DOI] [PubMed] [Google Scholar]
  23. Jackman A. L., Taylor G. A., Gibson W., Kimbell R., Brown M., Calvert A. H., Judson I. R., Hughes L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 1991 Oct 15;51(20):5579–5586. [PubMed] [Google Scholar]
  24. Jackman A. L., Taylor G. A., O'Connor B. M., Bishop J. A., Moran R. G., Calvert A. H. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. Cancer Res. 1990 Sep 1;50(17):5212–5218. [PubMed] [Google Scholar]
  25. Jansen G., Schornagel J. H., Westerhof G. R., Rijksen G., Newell D. R., Jackman A. L. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors. Cancer Res. 1990 Dec 1;50(23):7544–7548. [PubMed] [Google Scholar]
  26. Jenh C. H., Geyer P. K., Baskin F., Johnson L. F. Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. Mol Pharmacol. 1985 Jul;28(1):80–85. [PubMed] [Google Scholar]
  27. Jolivet J., Chabner B. A. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase. J Clin Invest. 1983 Sep;72(3):773–778. doi: 10.1172/JCI111048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Jones T. R., Calvert A. H., Jackman A. L., Brown S. J., Jones M., Harrap K. R. A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Eur J Cancer. 1981 Jan;17(1):11–19. doi: 10.1016/0014-2964(81)90206-1. [DOI] [PubMed] [Google Scholar]
  29. Jones T. R., Thornton T. J., Flinn A., Jackman A. L., Newell D. R., Calvert A. H. Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency. J Med Chem. 1989 Apr;32(4):847–852. doi: 10.1021/jm00124a018. [DOI] [PubMed] [Google Scholar]
  30. Koizumi S., Allegra C. J. Enzyme studies of methotrexate-resistant human leukemic cell (K562) subclones. Leuk Res. 1992 Jun-Jul;16(6-7):565–569. doi: 10.1016/0145-2126(92)90003-p. [DOI] [PubMed] [Google Scholar]
  31. Li W. W., Waltham M., Tong W., Schweitzer B. I., Bertino J. R. Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX). Adv Exp Med Biol. 1993;338:635–638. doi: 10.1007/978-1-4615-2960-6_131. [DOI] [PubMed] [Google Scholar]
  32. Marsham P. R., Hughes L. R., Jackman A. L., Hayter A. J., Oldfield J., Wardleworth J. M., Bishop J. A., O'Connor B. M., Calvert A. H. Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications. J Med Chem. 1991 May;34(5):1594–1605. doi: 10.1021/jm00109a011. [DOI] [PubMed] [Google Scholar]
  33. McBurney M. W., Whitmore G. F. Isolation and biochemical characterization of folate deficient mutants of Chinese hamster cells. Cell. 1974 Jul;2(3):173–182. doi: 10.1016/0092-8674(74)90091-9. [DOI] [PubMed] [Google Scholar]
  34. McCloskey D. E., McGuire J. J., Russell C. A., Rowan B. G., Bertino J. R., Pizzorno G., Mini E. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem. 1991 Apr 5;266(10):6181–6187. [PubMed] [Google Scholar]
  35. O'Connor B. M., Jackman A. L., Crossley P. H., Freemantle S. E., Lunec J., Calvert A. H. Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor. Cancer Res. 1992 Mar 1;52(5):1137–1143. [PubMed] [Google Scholar]
  36. Pavlovic M., Leffert J. J., Russello O., Bunni M. A., Beardsley G. P., Priest D. G., Pizzorno G. Altered transport of folic acid and antifolates through the carrier mediated reduced folate transport system in a human leukemia cell line resistant to (6R) 5,10-dideazatetrahydrofolic acid (DDATHF). Adv Exp Med Biol. 1993;338:775–778. doi: 10.1007/978-1-4615-2960-6_162. [DOI] [PubMed] [Google Scholar]
  37. Piall E. M., Curtin N. J., Aherne G. W., Harris A. L., Marks V. The quantitation by radioimmunoassay of 2'-deoxyuridine 5'-triphosphate in extracts of thymidylate synthase-inhibited cells. Anal Biochem. 1989 Mar;177(2):347–352. doi: 10.1016/0003-2697(89)90064-x. [DOI] [PubMed] [Google Scholar]
  38. Pizzorno G., Chang Y. M., McGuire J. J., Bertino J. R. Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. Cancer Res. 1989 Oct 1;49(19):5275–5280. [PubMed] [Google Scholar]
  39. Pizzorno G., Mini E., Coronnello M., McGuire J. J., Moroson B. A., Cashmore A. R., Dreyer R. N., Lin J. T., Mazzei T., Periti P. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res. 1988 Apr 15;48(8):2149–2155. [PubMed] [Google Scholar]
  40. Priest D. G., Ledford B. E., Doig M. T. Increased thymidylate synthetase in 5-fluorodeoxyuridine resistant cultured hepatoma cells. Biochem Pharmacol. 1980 Jun 1;29(11):1549–1553. doi: 10.1016/0006-2952(80)90607-3. [DOI] [PubMed] [Google Scholar]
  41. Rhee M. S., Wang Y., Nair M. G., Galivan J. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res. 1993 May 15;53(10 Suppl):2227–2230. [PubMed] [Google Scholar]
  42. Rossana C., Gollakota Rao L., Johnson L. F. Thymidylate synthetase overproduction in 5-fluorodeoxyuridine-resistant mouse fibroblasts. Mol Cell Biol. 1982 Sep;2(9):1118–1125. doi: 10.1128/mcb.2.9.1118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Samuels L. L., Goutas L. J., Priest D. G., Piper J. R., Sirotnak F. M. Hydrolytic cleavage of methotrexate gamma-polyglutamates by folylpolyglutamyl hydrolase derived from various tumors and normal tissues of the mouse. Cancer Res. 1986 May;46(5):2230–2235. [PubMed] [Google Scholar]
  44. Sanghani P. C., Jackman A., Evans V. R., Thornton T., Hughes L., Calvert A. H., Moran R. G. A strategy for the design of membrane-permeable folypoly-gamma-glutamate synthetase inhibitors: "bay-region"-substituted 2-desamino-2-methyl-5,8-dideazafolate analogs. Mol Pharmacol. 1994 Feb;45(2):341–351. [PubMed] [Google Scholar]
  45. Sikora E., Jackman A. L., Newell D. R., Calvert A. H. Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro. Biochem Pharmacol. 1988 Nov 1;37(21):4047–4054. doi: 10.1016/0006-2952(88)90094-9. [DOI] [PubMed] [Google Scholar]
  46. Szeto D. W., Cheng Y. C., Rosowsky A., Yu C. S., Modest E. J., Piper J. R., Temple C., Jr, Elliott R. D., Rose J. D., Montgomery J. A. Human thymidylate synthetase--III. Effects of methotrexate and folate analogs. Biochem Pharmacol. 1979 Sep 1;28(17):2633–2637. doi: 10.1016/0006-2952(79)90039-x. [DOI] [PubMed] [Google Scholar]
  47. Ward W. H., Kimbell R., Jackman A. L. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem Pharmacol. 1992 May 8;43(9):2029–2031. doi: 10.1016/0006-2952(92)90646-z. [DOI] [PubMed] [Google Scholar]
  48. Webber S. E., Bleckman T. M., Attard J., Deal J. G., Kathardekar V., Welsh K. M., Webber S., Janson C. A., Matthews D. A., Smith W. W. Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J Med Chem. 1993 Mar 19;36(6):733–746. doi: 10.1021/jm00058a010. [DOI] [PubMed] [Google Scholar]
  49. van der Laan B. F., Jansen G., Kathmann I., Schornagel J. H., Hordijk G. J. Mechanisms of acquired resistance to methotrexate in a human squamous carcinoma cell line of the head and neck, exposed to different treatment schedules. Eur J Cancer. 1991;27(10):1274–1278. doi: 10.1016/0277-5379(91)90096-v. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES